Spero Therapeutics Q1 2024 GAAP EPS $(0.24) Misses $(0.04) Estimate, Sales $9.267M Miss $21.533M Estimate
Spero Therapeutics Q1 2024 GAAP EPS $(0.24) Misses $(0.04) Estimate, Sales $9.267M Miss $21.533M Estimate
Spero Therapeutics 2024年第一季度GAAP每股收益美元（0.24）未達到預期（0.04），銷售額爲926.7萬美元，未達到215.33萬美元的預期
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.04) by 500 percent. This is a 4 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $9.267 million which missed the analyst consensus estimate of $21.533 million by 56.96 percent. This is a 347.90 percent increase over sales of $2.069 million the same period last year.
Spero Therapeutics（納斯達克股票代碼：SPRO）公佈的季度虧損爲每股0.24美元，比分析師普遍預期的0.04美元（0.04美元）低500％。這比去年同期每股虧損0.25美元（0.25美元）增長了4％。該公司公佈的季度銷售額爲926.7萬美元，比分析師普遍預期的215.33萬美元低56.96％。這比去年同期的206.9萬美元銷售額增長了347.90％。